

Beena akolkar

Discloser Identifier: 700233

Disclosure Purpose: 22-16477

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

SARS-CoV-2 - No Increased Islet Autoimmunity or Type 1 Diabetes in Teens

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

WILLIAM HAGOPIAN

Discloser Identifier: 559345

Disclosure Purpose: 22-16477

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Provention Bio	Grant / Contract	Self
Recipient Name: William Hagopian Recipient Type: Institution Grant / Contract Description: support for CASCADE Study to predict type 1 diabetes in children Grant / Contract Purpose: Research Additional Information:		
SANOPI PASTEUR INC.	Consultant	Self
Category: Consultant Description: consultant for early stage type 1 diabetes registry Additional Information: just 6 hours involvement so far		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

SARS-CoV-2 -- No Increased Islet Autoimmunity or Type 1 Diabetes in Teens

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 377593**Disclosure Purpose:** 22-16477

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

A Lack of Evidence that SARS-COV-2 Infection Promotes an Increased Risk of Islet Autoimmunity or type 1 diabetes in Adolescents: the TEDDY Study

3. **Are you the corresponding author?**

Yes.

- a. **Please list the other authors' names here.**

Åke Lernmark, Ph.D., William A. Hagopian, M.D., Ph.D., Marian J. Rewers, M.D., Ph.D., Richard McIndoe, Ph.D., Jorma Toppari, M.D., Ph.D., Anette-G. Ziegler, M.D., Beena Akolkar, Ph.D., on behalf of the TEDDY Study Group*

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 385018

Disclosure Purpose: 22-16477

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Diamyd Medical AB	Data And Safety Monitoring	Self
<p>Category: Data And Safety Monitoring Description: Treatment of Respiratory complications associated with Covid-19 infection using Wharton's Jelly (WJ)- Umbilical Cord (UC) mesenchymal stromal cells (PorTrans): open Phase 1B clinical trial; EudraCT number: 2020-002078-29 Additional Information:</p>		
Diamyd Medical AB	Consultant	Self
<p>Category: Consultant Description: Internal core competences constitute Diamyd Medical's core employees in collaboration with a global network of clinics, researchers and production units. Further expertise, including analysis- and laboratory services are contracted as needed. Additional Information:</p>		

Intellectual Property

Type	Is Licensed	Interest Held By
Patent - Cloning and expression of human islet glutamic ac	-	Self
<p>Description: Cloning and expression of human islet glutamic acid decarboxylase autoantigen. 6,025,176. Patent Status: Issued Filing Jurisdiction: USA Licensees: Additional Information:</p> <p>Patent Number: 6,025,176 Patent Holder: Previous Institution</p>		
Patent - Diagnosis of Insulin-dependent diabetes.	-	Self
<p>Description: Diagnosis of Insulin-dependent diabetes. Patent Status: Issued Filing Jurisdiction: USA Licensees: Additional Information:</p> <p>Patent Number: 5,547,847 Patent Holder: Previous Institution</p>		
Patent - Methods for determination of tissue types coded b	-	Self
<p>Description: Methods for determination of tissue types coded by MHC genes. Patent Status: Issued Filing Jurisdiction: EU Licensees: Additional Information:</p> <p>Patent Number: Patent EP 0103 000 B1 Patent Holder: Discloser</p>		
Patent - Cloning and expression of human islet glutamic ac	-	Self

Type	Is Licensed	Interest Held By
Description: Cloning and expression of human islet glutamic acid decarboxylase autoantigen. Patent Status: Issued Filing Jurisdiction: USA Licensees: Additional Information:	Patent Number: 5, 792,620 Patent Holder: Other Organization - Dedicated to the public on April 24, 2000	
Patent - Modified glutamic acid decarboxylase (GAD).	-	Self
Description: Modified glutamic acid decarboxylase (GAD). Patent Status: Issued Filing Jurisdiction: USA Licensees: Additional Information:	Patent Number: 6,093,396 Patent Holder: Other Organization - DiaMyd Medical AB, Stockholm, Sweden	

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

SARS-CoV-2 - No Increased Islet Autoimmunity or Type 1 Diabetes in Teens

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Richard McIndoe

Discloser Identifier: 1107711

Disclosure Purpose: 22-16477

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

SARS-CoV-2 -- No Increased Islet Autoimmunity or Type 1 Diabetes in Teens

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 1054771

Disclosure Purpose: 22-16477

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Janssen Research and Development	Consultant	Self
Category: Consultant Description: Paid to University Colorado Medicine Additional Information: Provide inputs into predictive tool for T1D screening, including, but not limited to: generation and use of predictive models of T1D risk using genetic risk scores, combined risk scores, demographics, morphometrics and medical history, organ-specific autoantibodies, and measurement methods for the above parameters. □ Attend discussions and provide data and data sources to input into the T1D screening tool.		
Provention Bio	Consultant	Self
Category: Consultant Description: Paid to University Colorado Medicine Additional Information: National Virtual Advisory Board		
SANOFI US SERVICES INC.	Consultant	Self
Category: Consultant Description: Screening the Landscape of T1D, paid to University Colorado Medicine Additional Information:		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

SARS-CoV-2 -- No Increased Islet Autoimmunity or Type 1 Diabetes in Teens

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Jorma Toppari

Discloser Identifier: 5059

Disclosure Purpose: 22-16477

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Diamyd Medical	Data And Safety Monitoring	Self
Category: Data And Safety Monitoring Description: DSMB member of Diagnode-3 trial Additional Information:		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

SARS-CoV-2 -- No Increased Islet Autoimmunity or Type 1 Diabetes in Teens

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

xAnette-Gabriele Ziegler

Discloser Identifier: 468203

Disclosure Purpose: 22-16477

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

SARS-CoV-2 - No Increased Islet Autoimmunity or Type 1 Diabetes in Teens

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.